UBS AM’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
UBS AM's ANTX Position: Q3 2026 in Review
UBS AM opened a new position in AN2 Therapeutics (ANTX) in Q3 2026: 177 shares worth $942. The stake represents ﹤0.01% of the portfolio and ranks #4132 among its holdings. This is a return to the name: UBS AM previously reported a position in ANTX as recently as Q1 2024.
UBS AM first reported a position in ANTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $248K in Q1 2024. 67 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- UBS AM held 177 shares of AN2 Therapeutics worth $942 as of Q3 2026.
- AN2 Therapeutics was a new UBS AM position in Q3 2026.
- AN2 Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4132 holding.
- UBS AM first reported a position in AN2 Therapeutics in Q1 2024 and has held it in 2 quarters since.
- UBS AM's AN2 Therapeutics position peaked at $248K in Q1 2024.
- 67 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.